Infectious Diseases Search
Infectious Diseases Infectious Diseases
rosacea
ROSACEA
Rosacea is a chronic cutaneous disease of the convexities of the central face (cheeks, chin, nose and central forehead) w/ periorbital and perioral skin sparing. This condition is attributed to chronic vasodilation.
Remissions and exacerbations are common.
It typically appears after 30 years of age but may occur at any age.  It commonly affects fair-skinned individuals.
The common presenting symptoms are facial flushing, stinging/burning erythema, telangiectasia, edema, papules, pustules, ocular lesions, and hypertrophy of the sebaceous glands of the nose with fibrosis.
A history of episodic flushing often heralds onset of rosacea.

Patient Education

  • Patient should be informed that there is no cure for rosacea & that the available treatment options can only delay the progression of symptoms
  • The most important steps are to avoid precipitating & aggravating factors
  • Educate on the regular use of sunscreens, proper skin care, & importance of follow-up for ocular symptoms
  • Consider a referral to:
    • A dermatologist if symptoms are more severe & acne are refractory to treatment
    • An ophthalmologist if patients w/ ocular rosacea have persistent or serious ocular symptoms
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
HKU investigators discover EBV variants strongly associated with nasopharyngeal cancer
Dr. Joseph Delano Fule Robles, 12 Feb 2019

A team of investigators from the University of Hong Kong (HKU) identified high-risk Epstein Barr virus (EBV) variants present in 97 percent of nasopharyngeal carcinoma (NPC) cases.

Original New Drug Application Approvals by US FDA (01- 15 February 2019)
5 days ago
New drug applications approved by US FDA as of 01- 15 February 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
CD4/CD8 ratio may predict risk of Kaposi sarcoma, NHL in HIV patients
Pearl Toh, 23 Aug 2018
Restoration of CD4/CD8 ratio on combination antiretroviral therapy (cART) was associated with decreased risk of Kaposi sarcoma (KS) while baseline CD8 count was related to non-Hogkin lymphoma (NHL) risk in people living with HIV (PLHIV) who had achieved viral suppression on cART, according to the COHERE* study presented at the AIDS International Conference (AIC) 2018.
Once-daily sofosbuvir-velpatasvir regimen effective in Asians with chronic HCV
Roshini Claire Anthony, 16 Jan 2019

A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.